Dr Timothy SC Hinks
The Oxford severe asthma MDT and research nurse team
Dr Timothy SC Hinks
BMBCh MA (Cantab) FRCP PhD
Wellcome Trust Fellow & Honorary Consultant
- Wellcome Trust Career Development Fellow, Respiratory Immunology, Nuffield Dept of Medicine
- NIHR Oxford Biomedical Research Centre Senior Research Fellow
- Honorary Consultant, Oxford Special Airway Service, Respiratory Medicine, Oxford University Hospitals NHS Trust
Investigating immune responses in asthma and lung infections
My group investigate the immunopathogenesis of airway diseases and pulmonary infections. We have a specific focus on the roles of novel T cell subsets in the mucosal immunology of the airways, particularly in driving inflammation in asthma and during chronic airways infection.
After a background in translational research in T cell immunodiagnostics in tuberculosis I have been funded by fellowships from the Wellcome Trust, Academy of Medical Sciences and National Institute of Health Research to study novel T cell subsets in the airways in human asthma and more recently the roles of mucosal associated invariant T (MAIT) cells in ex vivo and murine models of infection with Haemophilus influenzae, Legionella and Influenza virus.
Our goal is to better understand the immune responses which protect us from lung infections or can drive airways inflammation, to help develop new treatments to prevent exacerbations of lung diseases and to accelerate the development of improved vaccines.
Innate T cells in airways disease
Airway epithelial cell biology
Azithromycin for mild-to-moderate COVID-19 - Authors' reply.
Hinks TSC. and ATOMIC2 trial authors None., (2021), The Lancet. Respiratory medicine, 9, e100 - e101
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells
Zhuang X. et al, (2021), iScience, 24, 103144 - 103144
Subcutaneous omalizumab for people with asthma
Donovan T. et al, (2021), Cochrane Database of Systematic Reviews, 2021
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.
Hinks TSC. et al, (2021), The Lancet. Respiratory medicine
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.
Zhuang X. et al, (2021), bioRxiv